



Centre de Recherche Translationnelle
en Transplantation et Immunologie

 Nantes
Université



 Inserm



The Avatar method: computation of synthetic data and application in health


Olivia Rousseau, CR2TI, Nantes Université

Conflict of interest

PA Gourraud is the founder of Methodomics(2008) and the co-founder of Big data Santé (2018). He consults for major pharmaceutical companies, and start-ups, all of which are handled through academic pipelines (AstraZeneca, Biogen, BostonScientific, Cook, Dicaposte, Edimark, Ellipses, Elsevier, Methodomics, Merck, Mérieux, Octopize, Sanofi-Genzyme). PA Gourraud is a volunteer board member at AXA non-for-profit mutual insurance company (2021). He has no prescription activity with either drugs or devices

Type of data

Sensitive data
Pseudonymized data
Anonymized/Synthetic data



Type of data

HEALTH DATA

Sensitive data

Pseudonymized data

Anonymized/Synthetic data



Type of data




Sensitive data

Pseudonymized data

HEALTH DATA

Anonymized/Synthetic data



Major issue: Reidentification risk

- GDPR: General Data Protection Regularization
- Evaluation of the robustness of an anonymization process:
 - Singling out
 - Linkability
 - Inference




<https://www.cnil.fr/fr/lanonymisation-de-donnees-personnelles>


Avatar method

Patient-centric approach

Overview of the Avatar method




Overview of the Avatar method




Security metrics

- Local cloaking



- Hidden rate




• True
• Avatar

Security metrics

- Local cloaking

- Hidden rate




Application in health

PRIMUS project

PRIMUS project



- Multiple sclerosis: autoimmune disease



- **Objective:** Facilitate treatment choice

- Clinical trial REFLEX :
 - Interferon beta-1a treatment doses study
- 518 patients
- 14 variables: 4 categorical and 10 continuous
- Treatments:
 - 172 patients: Placebo (Arm 0)
 - 171 patients: Treatment 3 time per week (Arm 1)
 - 175 patients: Treatment 1 time per week (Arm 2)

[https://doi.org/10.1016/S1474-4422\(11\)70262-9](https://doi.org/10.1016/S1474-4422(11)70262-9)

- Clinical trial REFLEX :
 - Interferon beta-1a treatment doses study
- 518 patients
- 14 variables
- Treatment
 - 172 patients: Placebo (Arm 0)
 - 171 patients: Treatment 3 time per week (Arm 1)
 - 175 patients: Treatment 1 time per week (Arm 2)

**Compare true and avatarized data
from published results**




[https://doi.org/10.1016/S1474-4422\(11\)70262-9](https://doi.org/10.1016/S1474-4422(11)70262-9)

Avatar method – Parameters tests



- Number of neighbors: $k \in \{2, 5, 10, 20, 50, 100, 250\}$

$ncp = 8$
 $\%var = 80$




Avatar method – Parameters tests

k

- Number of neighbors: $k \in \{2, 5, 10, 20, 50, 100, 250\}$

$ncp = 8$
 $\%var = 80$






Avatar method – Parameters tests



- % of explained variance: $\%var \in \{30, 50, 80, 90, 100\}$

$k = 10$




Avatar method – Parameters tests

ncp

- % of explained variance: $\%var \in \{30, 50, 80, 90, 100\}$


$k = 10$




Avatars robustness – 100 synthetic datasets

- Arm 1 vs Placebo – Treatment effect on McDonald criterion (Cox)

$ncp = 8$
 $\%var = 80$




$k = 10$




Avatars robustness – 100 synthetic datasets

- Arm 2 vs Placebo – Treatment effect on McDonald criterion (Cox)



$ncp = 8$
 $\%var = 80$



$k = 10$





Avatar method – Security metrics




Avatar method – Security metrics



$k = 10$




PRIMUS selected avatar



- $k = 10$
- $\%var = 80 \rightarrow ncp = 8$
- Hidden rate = 90%
- Local cloaking = 5


PRIMUS selected avatar

- Primary endpoint: McDonald criterion



PRIMUS selected avatar

- Secondary endpoint: clinically definite multiple sclerosis criterion



Conclusions & Perspectives

Conclusion

- No need to risk **re-identification** of patients
- **Avatar method** keeps global characteristics and protect patients

Conclusion

- No need to risk **re-identification** of patients
- **Avatar method** keeps global characteristics and protect patients

Data characteristics



Data security

Ongoing works & Perspectives



ICAN project – Intracranial aneurysm study



KTD-innov project – Kidney transplantation study
First year medical study grades database



Use of column weights parameter for multidimensional projection step

Acknowledgments

Team 3

Sophie Limou
Gilles Blancho
Pierre-Antoine Gourraud
Nicolas Vince
Fabienne Haspot
Sonia Bourguiba-Hachemi
Martin Morin
Venceslas Douillard
Léo Boussamet
Nayane Brito
Vincent Mauduit
Irène Charles
Axelle Durand
Rokhaya Ba
Sirine Sayadi
Chadia Ed Driouch
Stanislas Demuth
Lucas Béraud
Ketsia Mortant
Augustin Moreau
Julien Bouchet
Justine Baron
Hugo Barbot



Octopize

Olivier Breillacq
Mogan Guillaudeux
Julien Petot
Charles-Axel Dein
Tom Crasset
Gaël Russeil



Clinique des données

Matilde Karakachoff
Matthieu Wargny
Sandrine Coudol
Thomas Goronflot



CHU Rennes

Gilles Edan



Variables contribution

